{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:24:14Z","timestamp":1783949054245,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) is a notable health concern in immunocompromised individuals and presents as CMV reactivation (CMV infection) or CMV reactivation with tissue invasion (CMV disease). However, few studies have distinguished these CMV patterns during induction therapy for autoimmune inflammatory rheumatic diseases (AIIRDs). This study investigated the clinical characteristics of patients with CMV disease, diagnosed through histopathology, immunohistochemistry, or polymerase chain reaction, during induction therapy for AIIRDs in comparison with those of patients with CMV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included patients with AIIRDs undergoing remission induction therapy with glucocorticoids \u226520 mg\/day for \u22654 weeks, hospitalized between 2013 and 2024. Data on clinical characteristics, treatments, and outcomes were collected, and CMV disease, determined by histopathological findings, was compared with CMV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 82 patients administered AIIRDs and positive for CMV antigenemia, 14 had CMV disease and 68 had CMV infection. CMV disease was associated with lower platelet counts, higher aspartate aminotransferase\/alanine transaminase levels, and higher maximum antigenemia. The prevalence of coincident infections (93% vs. 32%) and mortality rate (57% vs. 24%) were higher in patients with CMV disease. Kaplan\u2013Meier analysis showed poorer survival for patients with CMV disease (log-rank test, p=0.027). Receiver operating characteristic analysis identified antigen count (cutoff: 36) as the best predictor of CMV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CMV disease during remission induction therapy for AIIRDs is associated with higher antigenemia, more coincident infections, and poorer survival compared with CMV infection. Identifying the risk factors for CMV disease, including antigenemia and coincident infections, can improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1696516","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:14:20Z","timestamp":1770880460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tissue-invasive CMV disease is associated with poor prognosis during remission induction therapy for autoimmune inflammatory rheumatic diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Hideki","family":"Oka","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital","place":["Kobe, Hyogo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital","place":["Kobe, Hyogo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Miyakoshi","sequence":"additional","affiliation":[{"name":"Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital","place":["Kobe, Hyogo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital","place":["Kobe, Hyogo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu094","article-title":"Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191","article-title":"The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1551264","article-title":"Risk factors for cytomegalovirus disease with cytomegalovirus re-activation in patients with rheumatic disease","volume":"30","author":"Kaneshita","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/pqa98i","article-title":"Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases","volume":"39","author":"Ota","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken231","article-title":"Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population","volume":"47","author":"Takizawa","year":"2008","journal-title":"Rheumatol (Oxf Engl)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323923","article-title":"Clinical features and prognosis of systemic lupus erythematosus complicated by active cytomegalovirus infection: a retrospective cohort study","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0519-3","article-title":"Reactivation of cytomegalovirus predicts poor prognosis in patients on intensive immunosuppressive treatment for collagen-vascular diseases","volume":"22","author":"Hanaoka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20926","DOI":"10.1038\/s41598-022-25451-4","article-title":"Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study","volume":"12","author":"Shimada","year":"2022","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-012-0651-8","article-title":"Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases","volume":"23","author":"Fujimoto","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1086\/508173","article-title":"Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1086\/514145","article-title":"Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation","volume":"176","author":"Cope","year":"1997","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07456-2","article-title":"The clinical and immunological features of CMV infection in rheumatic patients: a nested case-control study","volume":"44","author":"Wu","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07609-3","article-title":"Risk factors of cytomegalovirus reactivation in patients with rheumatic musculoskeletal diseases undergoing remission induction therapy with high-dose glucocorticoids; a prospective short-term cohort study","volume":"44","author":"Ota","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.6.1084","article-title":"Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus","volume":"153","author":"Schrier","year":"1986","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.477","article-title":"Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor","volume":"182","author":"Frascaroli","year":"2009","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u2018indirect\u2019 effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05878-11","article-title":"Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells","volume":"85","author":"Reeves","year":"2011","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014509107","article-title":"Experimental human cytomegalovirus latency in CD14+ monocytes","volume":"107","author":"Hargett","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1006\/viro.1995.1143","article-title":"Stimulation of the human cytomegalovirus IE enhancer\/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB","volume":"208","author":"Pr\u00f6sch","year":"1995","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05196-z","article-title":"Clinical significance of cytomegalovirus (CMV) pp65 antigenemia in the prediction of CMV infection during immunosuppressive therapy for rheumatic disease","volume":"43","author":"Suga","year":"2023","journal-title":"Rheumatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: A randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub5","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:27:22Z","timestamp":1771928842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1696516"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1696516","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1696516"}}